Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
NASDAQ:AMEX Investor Relations:
ir.canfite.com
Company Research
Source: GlobeNewswire
Namodenoson, a Phase III cancer drug has strong potential in veterinary oncology, a market projected to reach $3.1 billion by 2030 Piclidenoson is currently in development for the treatment of osteoarthritis in pets; Clinical studies show efficacy in dogs, representing a $3 billion market RAMAT GAN, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today that it will participate in BioFIT 2025, which will be held on December 2–3, 2025, in Strasbourg, France. BioFIT 2025 is a major European conference focused on life sciences, bringing together academia, industry, and investors to facilitate technology transfer, early-stage collaborations, and investment in biotech and medtech. “Our previous participation at BioFIT led directly to our successful partnership with Vetbiolix for Piclidenoson fo
Show less
Read more
Impact Snapshot
Event Time:
CANF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CANF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CANF alerts
High impacting Can-Fite Biopharma Ltd Sponsored ADR (Israel) news events
Weekly update
A roundup of the hottest topics
CANF
News
- Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity ConferenceGlobeNewswire
- Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in BrazilGlobeNewswire
- Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.MarketBeat
- Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson [Yahoo! Finance]Yahoo! Finance
- Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with NamodenosonGlobeNewswire
CANF
Analyst Actions
- 11/4/25 - HC Wainwright
CANF
Sec Filings
- 11/21/25 - Form 424B3
- 11/21/25 - Form 6-K
- 11/20/25 - Form 6-K
- CANF's page on the SEC website